{"id":"W2072767047","doi":"10.1158/1535-7163.targ-11-b49","title":"Abstract B49: GRN1005 phase I studies: Final results.","year":2011,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer, Hypoxia, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"ca_institutions":"Angiochem (Canada)","funders":"","keywords":"Tolerability; Pharmacokinetics; Immunogenicity; Medicine; Glioma; Brain tumor; Pharmacology; Transcytosis; Paclitaxel; Cancer; Internal medicine; Cancer research; Oncology; Receptor; Antibody; Immunology; Adverse effect; Pathology; Endocytosis","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002356496,0.001506386,0.001238752,0.0004200381,0.0003120795,0.0008963984,0.001193542,0.001502746,0.007943072],"category_scores_gemma":[0.0009419063,0.000392713,0.001115497,0.0003498809,0.0004952904,0.0004958785,0.0003338219,0.002970965,0.002908061],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008748002,"about_ca_system_score_gemma":0.001756873,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0013465,"about_ca_topic_score_gemma":0.001980463,"domain_scores_codex":[0.9995072,0.0002097835,0.00002914762,0.00006208104,0.00008745009,0.0001043084],"domain_scores_gemma":[0.9992269,0.0001226335,0.0001435765,0.0000913449,0.00009320881,0.0003224587],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.32811,0.06313352,0.005711751,0.003287162,0.002867619,0.0009523835,0.0003266904,0.005472107,0.2710202,0.0008960165,0.05538783,0.2628347],"study_design_scores_gemma":[0.2890123,0.5835008,0.02369295,0.0002598113,0.001505682,0.001541332,0.0000719008,0.002366839,0.05600707,0.0007870795,0.04118894,0.00006522613],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9155819,0.0147696,0.009495291,0.003033277,0.0008509141,0.01681385,0.01739939,0.001213326,0.02084251],"genre_scores_gemma":[0.9216506,0.007123974,0.01036539,0.004017226,0.0003723188,0.007705622,0.02435899,0.0002542216,0.02415154],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007943072,"threshold_uncertainty_score":0.02657217,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09631823802331448,"score_gpt":0.3538036902613952,"score_spread":0.2574854522380808,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}